Business Context and Reporting Period
This Form 8-K Current Report was filed by Graybug Vision, Inc. (not Calcimedica, Inc.) on April 18, 2022, regarding events occurring on April 13, 2022. The filing addresses changes to the Company's Board of Directors.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance changes.
Material Changes
- Resignation: Gerald D. Cagle, Ph.D., resigned as a Director and member of the Nominating and Corporate Governance Committee, effective April 13, 2022. He will continue as a paid advisor. The Company states there are no disagreements regarding his departure.
- Appointment: Dirk Sauer, Ph.D., was appointed as a Class I Director to fill the vacancy. He is expected to stand for election at the 2024 annual meeting.
- Compensation for New Director: Dr. Sauer will receive an annual cash retainer of $40,000 plus $4,000 for committee service. He also received an initial option grant for 80,000 shares of common stock, vesting annually over three years.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of material risks or contingencies. It notes that Dr. Sauer brings 31 years of experience from Novartis International AG in ophthalmology research and development.
Investor Verification Checklist
- Verify the ticker symbol GRAY on the Nasdaq Global Market.
- Confirm the terms of the 2020 Equity Incentive Plan regarding the 80,000 share option grant to Dr. Sauer.
- Review the attached press release (Exhibit 99.1) for additional context on the board changes.
- Note that the filing explicitly states the press release information is not "filed" for purposes of Section 18 of the Exchange Act.